Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Given Average Recommendation of “Hold” by Analysts

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) have been given an average recommendation of “Hold” by the five research firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $27.40.

A number of equities research analysts recently commented on the stock. BTIG Research reissued a “buy” rating and set a $32.00 target price on shares of Kestra Medical Technologies in a report on Tuesday, April 7th. Weiss Ratings cut shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 15th. Finally, The Goldman Sachs Group lowered their target price on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th.

Kestra Medical Technologies Trading Down 0.2%

NASDAQ:KMTS opened at $20.69 on Wednesday. The company has a current ratio of 7.32, a quick ratio of 7.32 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $1.21 billion, a PE ratio of -5.22 and a beta of 0.83. The firm’s 50 day moving average is $20.80 and its 200 day moving average is $22.78. Kestra Medical Technologies has a 12 month low of $13.25 and a 12 month high of $30.00.

Insider Transactions at Kestra Medical Technologies

In other Kestra Medical Technologies news, insider Brian Daniel Webster sold 15,000 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $20.81, for a total transaction of $312,150.00. Following the sale, the insider owned 395,467 shares of the company’s stock, valued at $8,229,668.27. The trade was a 3.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Over the last quarter, insiders have sold 45,000 shares of company stock worth $927,150. Insiders own 3.60% of the company’s stock.

Institutional Investors Weigh In On Kestra Medical Technologies

Hedge funds and other institutional investors have recently bought and sold shares of the business. Farther Finance Advisors LLC bought a new stake in Kestra Medical Technologies during the 4th quarter valued at $31,000. Russell Investments Group Ltd. grew its position in shares of Kestra Medical Technologies by 43.5% during the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after purchasing an additional 474 shares in the last quarter. BNP Paribas Financial Markets grew its position in shares of Kestra Medical Technologies by 148.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock valued at $65,000 after purchasing an additional 1,638 shares in the last quarter. Daiwa Securities Group Inc. purchased a new position in shares of Kestra Medical Technologies during the 4th quarter valued at $72,000. Finally, Brown Brothers Harriman & Co. grew its position in shares of Kestra Medical Technologies by 26.8% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock valued at $74,000 after purchasing an additional 656 shares in the last quarter.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.